# Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

> **NCT02148744** · PHASE1 · COMPLETED · sponsor: **Xencor, Inc.** · enrollment: 72 (actual)

## Conditions studied

- Allergic Rhinitis
- Allergic Conjunctivitis
- Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** XmAb7195
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02148744
- **Lead sponsor:** Xencor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-09-21
- **Final completion:** 2015-09-21
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02148744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02148744, "Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02148744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*